低恶性潜能卵巢肿瘤中的基质金属蛋白酶2和9及其组织抑制剂
Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
作者信息
Määttä M, Santala M, Soini Y, Talvensaari-Mattila A, Turpeenniemi-Hujanen T
机构信息
Department of Obstetrics and Gynecology, University of Oulu, Oulu, Finland.
出版信息
Tumour Biol. 2004 Jul-Aug;25(4):188-92. doi: 10.1159/000081101.
OBJECTIVES
This study aimed to analyze the expression of matrix metalloproteinases 2 (MMP-2) and 9 (MMP-9) and their tissue inhibitors TIMP-1 and TIMP-2 in low malignant potential (LMP) ovarian tumors and to compare these values with those recorded for benign and malignant ovarian neoplasms.
METHODS
A total of 53 ovarian tumors (16 benign, 15 LMP and 22 malignant) were evaluated by immunohistochemistry for the expression of MMP-2, MMP-9, TIMP-1 and TIMP-2.
RESULTS
MMP-2 expression was found in 56% of the benign, 40% of the LMP, and 90% of the malignant ovarian tumors (benign vs. malignant, p = 0.021; LMP vs. malignant, p = 0.002). The expression of MMP-9, TIMP-1 and TIMP-2 was lower in the benign and LMP tumors compared with the malignant ones.
CONCLUSION
The data suggest that, in relation to the expression of MMP-2, MMP-9, TIMP-1 and TIMP-2, LMP ovarian tumors are more similar to benign than to malignant ovarian tumors.
目的
本研究旨在分析基质金属蛋白酶2（MMP - 2）和9（MMP - 9）及其组织抑制剂TIMP - 1和TIMP - 2在低恶性潜能（LMP）卵巢肿瘤中的表达，并将这些值与良性和恶性卵巢肿瘤记录的值进行比较。
方法
通过免疫组织化学评估总共53个卵巢肿瘤（16个良性、15个LMP和22个恶性）中MMP - 2、MMP - 9、TIMP - 1和TIMP - 2的表达。
结果
在56%的良性卵巢肿瘤、40%的LMP卵巢肿瘤和90%的恶性卵巢肿瘤中发现MMP - 2表达（良性与恶性相比，p = 0.021；LMP与恶性相比，p = 0.002）。与恶性肿瘤相比，良性和LMP肿瘤中MMP - 9、TIMP - 1和TIMP - 2的表达较低。
结论
数据表明，就MMP - 2、MMP - 9、TIMP - 1和TIMP - 2的表达而言，LMP卵巢肿瘤与良性卵巢肿瘤比与恶性卵巢肿瘤更相似。
Zotero 插件